| 1 | Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England | | |
|----|---|--|--|
| 2 | | | |
| 3 | Pablo N Perez-Guzman ^{1,*} , MD, MSc, Edward Knock ^{1,*} , PhD, Natsuko Imai ¹ , PhD, Thomas Rawson ¹ , DPhil, Yasin | | |
| 4 | Elmaci ¹ , MSc, Joana Alcada ^{2,3} , MD, Lilith K Whittles ¹ , PhD, Divya Thekke Kanapram ^{1,4} , PhD, Raphael Sonabend ¹ , | | |
| 5 | PhD, Katy AM Gaythorpe ¹ , PhD, Wes Hinsley ¹ , PhD, Richard G FitzJohn ¹ , PhD, Erik Volz ¹ , PhD, Robert Verity ¹ , PhD, | | |
| 6 | Neil M Ferguson ¹ , DPhil, Anne Cori ¹ , PhD, Marc Baguelin ^{1,5,6} PhD | | |
| 7 | | | |
| 8 | 1. MRC Centre for Global Infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency | | |
| 9 | Analytics (J-IDEA), School of Public Health, Imperial College London, United Kingdom | | |
| 10 | 2. Adult Intensive Care Unit, Royal Brompton Hospital, London | | |
| 11 | 3. Department of Surgery and Cancer, Faculty of Medicine, Imperial College London | | |
| 12 | 4. Department of Engineering, Division of Electrical Engineering, University of Cambridge, United Kingdom | | |
| 13 | 5. National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Modelling and Health | | |
| 14 | Economics, London, United Kingdom | | |
| 15 | 6. Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, | | |
| 16 | London School of Hygiene & Tropical Medicine, London, United Kingdom | | |
| 17 | | | |
| 18 | 8 *Contributed equally | | |
| 19 | | | |
| 20 | Corresponding Author: | | |
| 21 | Dr Marc Baguelin, MRC Centre for Global Infectious Disease Analysis Department of Infectious Disease | | |
| 22 | Epidemiology, Faculty of Medicine at St Mary's Campus, Imperial College London, W2 1PG. UK. Email: | | |
| 23 | m.baguelin@imperial.ac.uk. Tel: 0044 20 7594 3290 | | |
| 24 | | | |

Abstract: As the SARS-CoV-2 pandemic progressed, distinct variants emerged and dominated in England. These

26 variants, Wildtype, Alpha, Delta, and Omicron were characterized by variations in transmissibility and severity. We 27 used a robust mathematical model and Bayesian inference framework to analyse epidemiological surveillance data from 28 England. We quantified the impact of non-pharmaceutical interventions (NPIs), therapeutics, and vaccination on virus 29 transmission and severity. Each successive variant had a higher intrinsic transmissibility. Omicron (BA.1) had the 30 highest basic reproduction number at 8.1 (95% credible interval (CrI) 6.8-9.3). Varying levels of NPIs were crucial in 31 controlling virus transmission until population immunity accumulated. Immune escape properties of Omicron decreased 32 effective levels of protection in the population by a third. Furthermore, in contrast to previous studies, we found Alpha 33 had the highest basic infection fatality ratio (2.8%, 95% CrI 2.3-3.2), followed by Delta (2.0%, 95% CrI 1.5-2.4), Wildtype (1.2%, 95% CrI 1.0-1.3), and Omicron (0.6%, 95% CrI 0.4-0.8). Our findings highlight the importance of 34 continued surveillance. Long-term strategies for monitoring and maintaining effective immunity against SARS-CoV-2 35 36 are critical to inform the role of NPIs to effectively manage future variants with potentially higher intrinsic 37 transmissibility and severe outcomes.

38

25

39

40 Main

The COVID-19 pandemic has driven unprecedented surges in excess mortality,¹ and caused severe disruptions to healthcare systems and economies globally.^{2,3} The Omicron sub-variants are more transmissible and thus more difficult to control than ancestral lineages;^{4,5} and their severity levels, although lower, remain a threat to populations and health systems.⁶

45

The global public health response to the virus has included varying degrees of non-pharmaceutical interventions (NPIs), improvement of treatment, and vaccination.⁷ The SARS-CoV-2 virus has evolved over time, with distinct variants of concern (VOCs) predominant during successive epidemic waves. Epidemiological studies have assessed changes in the transmissibility and severity of SARS-CoV-2 over these sequential waves of infections and the overall effectiveness of interventions.^{8–13} However, integrated quantitative analyses of the relative effect of different interventions and a direct comparison of the transmissibility and severity of different variants have not been performed to date.

53 Here we expanded a validated dynamic transmission model using a Bayesian evidence synthesis framework,⁸⁻¹⁰ and 54 fitted it to comprehensive surveillance data by age and English National Health Service (NHS) regions. Data included 55 the number of positive and negative PCR tests in the community, population-representative infection prevalence 56 surveys, genetic characterisation of a sample of the PCR positive cases, seroprevalence from blood donor residual sera, 57 hospital admissions and deaths, and community deaths (see Figure 1 A-B, methods and online Supplement). Leveraging 58 these data, we estimated the absolute and relative levels of transmissibility and severity of the Wildtype, Alpha, Delta, 59 and initial Omicron (BA.1) variants, and other key epidemiological parameters. We evaluated the relative effect of 60 changes in contact rates due to NPIs, changes in healthcare provision and clinical practice and infection- or vaccine-61 derived population immunity on virus transmission and severity in England between March 16, 2020 and February 24, 62 2022.

63

64 Evolving SARS-CoV-2 transmissibility and population infection control strategies

England experienced multiple COVID-19 waves, partly due to different SARS-CoV-2 variants over the study period (Figure 1A-B). The effective reproduction number, R_t^{eff} , quantifies viral transmissibility over time and represents the average number of secondary infections each primary infection generates at time *t*, with $R_t^{eff} < 1$ indicating epidemic decline and $R_t^{eff} > 1$ epidemic growth.¹⁴ R_t^{eff} is determined by the inherent transmission potential of a variant and by contact patterns and immunity levels in the host population.¹⁴ We estimated both R_t^{eff} and the time-varying reproduction number in the absence of population immunity, R_t . The latter allows us to disentangle the intrinsic and extrinsic factors that drive transmissibility, with the basic reproduction number, R_0 , defined as $R_{t=0}$.

72

Viral evolution tends to select for more transmissible lineages.¹⁵ For the Alpha and Delta variants, mutations in the spike protein that conferred higher receptor affinity and faster fusion into host cells increased intrinsic transmissibility.¹⁶ The later Omicron (BA.1) variant had further mutations allowing substantial immune escape.¹⁶ The R_0 of SARS-CoV-2 variants in England sequentially increased from 2.5 (95% credible interval (CrI) 2.1 – 2.8) for the initial Wildtype virus, to 4.0 (95% CrI 3.5 – 4.5), 6.7 (95% CrI 5.7 – 7.7) and 8.1 (95% CrI 6.8 – 9.3), respectively, for the Alpha, Delta and Omicron (BA.1) variants (Figure 1D).

NPIs were first introduced in England in mid-March 2020, during the first epidemic wave, to reduce transmission through social distancing, and limit numbers of severe cases from overwhelming the health system.¹⁷ These measures were lifted and re-implemented thereafter, at varying levels, through to late February 2022.⁷ R_t varied as contact rates decreased or increased in response to NPIs (Figure 1F). Before the COVID-19 vaccination programme, R_t^{eff} was only slightly lower than R_t , indicating very low levels of accrued infection-induced immunity. We estimate that only 7.7% (95% CrI 7.2 – 8.3) of the population were immune by early September 2020, before the emergence of the Alpha variant (Figure 1G).


87


88 The rollout and scale-up of the national vaccination programme, from December 2020 onwards, coincided with the 89 dominance of more transmissible VOCs. Nevertheless, rapidly increasing immunity helped limit the spread of the Alpha 90 and Delta variants (Figure 1E & G). Error! Reference source not found.Population-level protection against infection 91 rapidly rose from 12.4% (95% CrI 11.8 – 13.0), purely from prior infections, on December 8, 2020, to 33.9% (95% CrI 92 33.0 - 34.9) by the time Delta emerged in March 2021 due to a combination of infection- and vaccine-induced immunity. 93 We estimate population-level immunity peaked at 67.8% (95% CrI 66.2-69.4) in late November 2021, with vaccination 94 contributing the most to this immunity profile (Figure 1G). During this same period, in the summer of 2021, NPIs were progressively lifted with the national policy for a Roadmap out of lockdown.^{7,17} R_t increased gradually as NPIs were 95 96 lifted in the first half of 2021, leading to a sustained high level of Delta infections for 5 months (Figure 1A). During this period, R_t^{eff} estimates remained close to 1 (Figure 1F), suggesting increases in contact rates were balanced by increasing 97 98 immunity for an extended period.

99

100 In contrast, the emergence and dominance of the initial Omicron BA.1 variant marked a decline in population immunity 101 (Figure 1G). The relative increase in Omicron's R_0 compared with Delta was not as high compared to previous variant replacements (Figure 1D). Rather, the replacement of the Delta variant by Omicron was driven by the antigenic 102 divergence and thus immune escape properties of Omicron relative to prior variants with population-level protection 103 against infection decreasing by 31% of its late November peak value to reach 46.9% (95% CrI 45.6 – 48.0) in late 104 105 December 2021 (Figure 1G). Infection levels rose to an all-time high over this period, with re-infections accounting for up to a third of daily new infections (Figure 1C). Reimplementation of some NPIs (work from home and wearing face 106 masks and/or showing proof of negative COVID-19 tests in public venues)^{7,18} introduced between December 12, 2021 107

- 108 and January 27, 2022, decreased R_t (Figure 1F). Nevertheless, we estimate that the combined effect of rapidly rolling
- 109 out booster vaccinations and infection-induced immunity, increased population-level immunity and, consequently,
- 110 decreased R_t^{eff} to around 1 (Figure 1F-G). By February 24, 2022, when all NPIs were lifted and large parts of routine
- surveillance were phased out,⁷ population protection against infection was 53.0% (95% CrI 50.6 55.5), with 20.1%
- 112 (95% CrI 19.7 20.6) resulting from vaccination, 9.7% (95% CrI 9.1 10.2) from prior infection, and 23.2% (95% CrI
- 113 21.8 24.7) from a combination of both (Figure 1G).
- 114





- 132 effective protection against specific variants, with colour scheme as in panels C & D, whereas areas indicate overall
- 133 effective protection by type of immunity (vaccine derived, hybrid or natural from prior infection). During periods of
- 134 variant replacement (e.g. Alpha to Delta) the effective protection transitions from the levels associated with the variant
- being replaced to the level of the variant that becomes dominant.
- 136
- 137

- 138
- 139

Epidemiological drivers of the severity of COVID-19 waves 140

141 The severity of SARS-CoV-2 across multiple epidemic waves in England varied substantially over the study period (Figure 2A-C). Observable severity as traditionally measured from epidemiological surveillance, however, is subject to 142 a range of biases, including case ascertainment, healthcare provision and population immunity.¹⁹ Therefore, traditional 143 surveillance cannot directly quantify the intrinsic severity of pathogens, nor disentangle the effects of underlying factors 144 145 on severity.

146

Our model captures temporal changes in the infection hospitalisation ratio (IHR, probability of hospitalisation given 147 infection), hospital fatality ratio (HFR, probability of death given hospitalisation for severe disease), and infection 148 149 fatality ratio (IFR, probability of death given infection) by SARS-CoV-2 variant. During the time of the study, the virus ecosystem underwent many transformations, with changes taking place for example in the virus biology, the surveillance 150 landscape and the healthcare system. To enable a like-for-like comparison of variant severity, we defined the variant-151 specific basic IHR, HFR and IFR as that observed in an entirely immunologically naïve population with the same age 152 153 distribution of infections and healthcare provision that was seen after the peak of the first wave of the pandemic (see 154 Supplement section 4.7). We also model changes in healthcare provision and changes in clinical practice throughout the duration in the study using a time varying piece-wise linear function (see Supplement Table S9). Despite the large 155 amount of data used to inform the model, it can be challenging, if events happen simultaneously, to pinpoint which 156 157 specific event affected changes in severity.

158

The basic IHR of SARS-CoV-2 increased from 2.2% (95% CrI 2.0 – 2.5) for Wildtype, to 3.5% (95% CrI 3.1 – 3.9) for 159 Alpha, 4.4% (95% CrI 4.0 – 4.9) for Delta, but subsequently decreased to 3.5% (95% CrI 2.8 – 4.4) for Omicron (Figure 160 2A). The overall risk of dving for hospitalised patients was highest for the Alpha variant, with a basic HFR of 47.8% 161 (95% CrI 37.8 – 55.9), lower for Wildtype and Delta, at 33.0% (95% CrI 28.8 – 37.4) and 29.7% (95% CrI 21.8 – 38.2), 162 respectively, and lowest for Omicron (BA.1), at 11.4% (95% CrI 7.3 – 16.3) (Figure 2B). The basic IFR was a function 163 of the basic IHR and HFR, further accounting for COVID-19 deaths in the community (outside hospitals). The basic 164

IFR was highest for the Alpha variant at 2.8% (95% CrI 2.3 – 3.2), followed by Delta at 2.0% (95% CrI 1.5 – 2.4),
Wildtype at 1.2% (95% CrI 1.0 – 1.3), and Omicron at 0.6% (95% CrI 0.4 – 0.8) (Figure 2C).


167

We also estimated the effective observable severity (given healthcare provision, immunity, and age-dependent mixing patterns) of the variants over time and estimated the effect of changes in healthcare practices and population immunity against severe outcomes. During the first epidemic wave, effective treatments, including remdesivir and dexamethasone, were approved and deployed,^{20,21} and there was a major re-adaptation of hospital capacity to manage severe COVID-19 cases.²² We infer that such changes in healthcare reduced the effective HFR, in line with prior observational evidence,¹¹ and IFR below basic levels for the then-dominant Wildtype variant (Figure 2B & C).

174

Our findings also suggest that pressures on the healthcare system had a detrimental impact on the severity of the 175 176 pandemic. Between October 2020 and January 2021, when a tiered geographically-localised system of NPIs in England was used¹⁷, infection incidence increased, associated with a sustained period when $R_t^{eff} > 1$ (Figure 1A, B & F). There 177 was a progressive increase in all effective severity metrics, particularly in HFR, (Figure 2A-C) as the model infers there 178 was an overall higher risk of death in hospital, independently of the basic severity properties of the Alpha variant. It 179 should be noted, no data was available on hospital admissions and deaths by variant to fit our model to and differentiate 180 the specific contribution of variant and healthcare effects on the increased severity. However, in an additional statistical 181 analysis using linked patient-level records, we observed that the increase in HFR during this period was positively 182 correlated with daily critical care bed occupancy levels, with variation across English regions (see Supplement section 183 184 6.1).

medRxiv preprint doi: https://doi.org/10.1101/2023.02.10.23285516; this version posted February 12, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .





187 Figure 2 – Inferred severity of SARS-CoV-2 variants in England between March 2020 and February 2022. A-C) Inferred basic and effective infection hospitalisation ratio (IHR, A), hospital fatality ratio (HFR, B) and infection fatality 188 ratio (IFR, C). Boxplots to the left show the basic severity measure and trajectories to the right show severity measure 189 over time (mean and 95% credible interval, 95% CrI) for each variant, with black showing the weighted average across 190 191 co-circulating variants at any time. Basic severity is measured for each variant assuming healthcare characteristics of 192 the early epidemic, to allow a like-for-like comparison. Effective severity trajectories account for changing vaccine- and infection-induced protection against severe disease, as well as underlying healthcare variations (see Table S8 for model 193 194 time-varying severity parameters).D-F) Age-specific (selected age groups) effective IHR (D), HFR (E) and IFR (F), 195 assessed at the date of key milestones of the national vaccination programme, "rollout" refers to the start of the 196 vaccination programme on 8th December 2020.

| 1 | 9 | 8 |
|---|---|---|
| | | |

199 Vaccination decisively reduced the effective severity of COVID-19 in England. As age is a major predictor of COVID-19 severity.²³ the national vaccination strategy prioritised the elderly and clinically vulnerable.²⁴ Our model reproduces 200 201 this prioritisation and complex observed dynamics of the age distribution of hospitalisations and deaths over time (see 202 Supplement Figure S11). We were, thus, able to infer the age-specific severity profile (see Model parameters were estimated as in calibration or informed by the literature (see Supplement Table S11). We ran sensitivity analyses for 203 parameters affecting the transmissibility of all the variants and, for the case of Omicron only, the cross-protection 204 205 conferred from a prior infection by any variant and the vaccine effectiveness of booster doses (see Supplement section 206 5). We found that qualitatively our estimates were robust to assumptions about the serial interval and effectiveness of booster vaccines. Similarly, varying assumptions about the cross-protection that infection with previous variants provide 207 against Omicron vielded very similar results to our main analysis.²⁵ 208

- 209
- 210

211 Discussion

Many factors influence pathogen transmission and severity, including pathogen evolution,¹⁵ intervention-based or self-212 adopted changes in behaviours,²⁶ and changing infection- and/or vaccine-induced protection.¹⁹ Estimating the relative 213 214 role of these factors in shaping an epidemic is difficult, as multiple complex interacting processes are involved, which are not directly measurable through surveillance.¹⁹ By retrospectively fitting a dynamic transmission model to the 215 uniquely rich COVID-19 epidemiological surveillance data from England²⁷ we provide the first quantitative estimates 216 217 of the population-level drivers of SARS-CoV-2 transmission and severity. Although our study focuses on England, the 218 results have implications for the effectiveness of control measures globally in this and future pandemics.

219

Prior to vaccinations when population immunity was low, only stringent levels of NPIs were effective in limiting virus 220 221 transmission. The intrinsic transmission advantage of Alpha and Delta allowed them to become dominant, while Omicron's additional immune escape properties, which reduced population-level protection against infection by 222 223 approximately a third, enabled it to become dominant from late 2021 despite the high population immunity at that time.

225 We find that the Alpha variant displayed the highest basic HFR and IFR, followed in decreasing order by the Delta, Wildtype and Omicron variants. A higher risk of hospitalisation and death has been estimated for the Delta variant 226 compared to Alpha in a previous meta-analysis.²⁸ The strongest evidence for this comes from a cohort study which 227 228 compared severity outcomes amongst individuals diagnosed in the community with a positive PCR test in England between late March and May, 2021.²⁹ Researchers from this study concluded that infections with the Delta variant 229 carried a significantly higher risk of hospitalisation and death, adjusting for a number of sociodemographic variables, 230 vaccination status and week of infection occurrence.²⁹ This and other studies,^{28,29} however, were restricted to short time 231 periods where both variants co-circulated and, hence, do not capture subsequent changes such as a reduction in severity 232 later in the Delta period with the AY.4.2 sub-variant compared with the earlier non-AY.4.2 one.³⁰ Moreover, survival 233 studies restricted to discrete periods are subject to biases inherent to health seeking and treatment practices. In this sense, 234 estimates of the increase severity of Delta over Alpha from patients seeking a PCR test are constrained by test-seeking 235 236 behaviours in the population during the early phase of Delta transmission. In contrast, we average variant specific estimates over a longer period, integrating them dynamically with other ecological factors, including infection 237 prevalence, PCR cases positivity and variant frequency in the latter. Whilst we did not have data available to fit our 238 model to hospital outcomes by variant, by integrating multiple data sources in a comprehensive evidence synthesis 239 240 framework, we disentangle and reproduce the multiple drivers of severity and estimate that the IFR for Alpha was higher 241 than for Delta. Indeed, future pandemic studies would benefit from additional surveillance data with distinction of 242 hospitalisations and deaths by pathogen strain.

243

In line with prior evidence,¹¹ our results show that a rapid identification of effective pharmacological treatments^{20,21} and 244 re-adaptation of hospital capacity²² were effective in countering the intrinsic severity of the Wildtype virus. However, 245 we and other authors^{31,32} also find strong evidence that improvements in clinical care can be nullified unless paired with 246 247 effective and timely interventions to control infection rates in the population. We find that NPIs were not always 248 effective or timely enough to control the virus. This led to a peak in hospitalisations over the winter of 2020/21 and, in 249 turn, an increase in HFR which could not be explained solely by the severity characteristics of the Wildtype and Alpha variants, nor changes in the age distribution of hospital admissions. Lastly, we have demonstrated the critical role of 250 risk-prioritised vaccination programmes²⁴ in reducing severity alongside transmission. Levels of protection from prior 251 252 infection in England have remained low throughout. The combined proportion of those effectively protected by

infection-induced and combined infection- and vaccine-induced immunity has stayed under a third of the national population.

255

Currently, the Omicron variant lineage dominates the pandemic landscape globally.²⁵ Our analysis robustly shows that 256 the initial (BA.1) sub-variant of this lineage has basic severity properties comparable to Wildtype IHR, HFR and IFR. 257 Recent analyses from China, where cumulative levels of protection against the virus in the population are considerably 258 lower than in England, suggest that NPIs remain crucial public health interventions.⁶ We have demonstrated that a 259 failure to mitigate transmission early can lead to increased severity and pressure on health services. Further research is 260 261 needed to quantify the impact of changes in healthcare pressure metrics such as staff-to-patient ratios, safe bed occupancy, and availability of key commodities, which could be monitored for real-time epidemic analyses and 262 263 integrated in future pandemic disease models.

264

Models can be used to systematically explore uncertainties around the target population and vaccination programmes 265 for pandemic and seasonal respiratory pathogens.³³⁻³⁵ Waning vaccine- and infection-induced immunity against 266 Omicron subvariants is well established,^{4,12,36} and recent studies suggest that hybrid immunity (from prior infection and 267 vaccination) may be more effective than repetitive boosting through vaccination.³⁷ Yet, our analysis around the 268 269 emergence of the Omicron variant demonstrates that boosting immunity by vaccination remains an important intervention to tackle potential changes in the transmissibility and severity of SARS-CoV-2 as it evolves. Despite recent 270 optimism that COVID-19 is becoming endemic,³⁸ the risk of new SARS-CoV-2 variants emerging remains.² We have 271 272 highlighted the public health implications of a higher viral transmissibility over time, which has resulted from both 273 increased intrinsic transmissibility and increased immune escape properties. Even with similar severity properties to the 274 current Omicron lineage, a variant with a higher intrinsic transmissibility will pose a significant public health threat.⁶

275

As COVID-19 surveillance has been drastically scaled down,⁷ detecting future changes in the characteristics of SARS-CoV-2 and performing robust epidemiological analyses will be challenging. Our study highlights the importance of comprehensive quantitative frameworks to integrate evidence from multiple data streams. We demonstrate how combining data from different sources can help to identify patterns that may not be apparent (or would be wrongly attributed), such as the higher IFR estimated for Alpha than Delta in contrast to previous studies, when using a reduced

number of data streams. This in turn provides important insights into the drivers of epidemic dynamics and informs options for future interventions. As the pandemic continues, optimising surveillance systems to detect significant changes in viral severity and transmissibility, trends in global case numbers, and the emergence of new VOCs is critical.

284

285 Declaration of interests

286

PPG has consulted for Pfizer. AC has received payment from Pfizer for teaching of mathematical modelling of infectious diseases. RS and NI are currently employed by the Wellcome Trust, however the Wellcome Trust had no role in the study design, data collection, data analysis, data interpretation or writing of the manuscript. KAMG has received honoraria from Wellcome Genome Campus for lectures and salary support from the Bill & Melinda Gates Foundation and Gavi, the Vaccine Alliance, through Imperial College London for work outside this study. LKW has received consultancy payments from the Wellcome Trust. All other authors declare no competing interests. All other authors declare no competing interests.

294

295 Acknowledgments

296

297 We thank all colleagues at PHE and front-line health professionals who have not only driven and continue to drive the daily response to the COVID-19 epidemic in England but also provided the necessary data to inform this study. This 298 299 work would not have been possible without the dedication and expertise of said colleagues and professionals. The use 300 of pillar-2 PCR testing data, vaccination data, and the variant and mutation data was made possible thanks to PHE colleagues, and we extend our thanks to N Gent and A Charlett for facilitation and insights into these data. The use of 301 302 serological data was made possible by colleagues at PHE Porton Down, Colindale, and the NHS Blood Transfusion Service. We are particularly grateful to G Amirthalingam and N Andrews for helpful discussions around these data. 303 304 We thank all the REal-time Assessment of Community Transmission (REACT) Study investigators for sharing PCR 305 prevalence data. We also thank the entire Imperial College London COVID-19 response team for support and feedback throughout. The views expressed are those of the authors and not necessarily those of the UK Department of 306 Health and Social Care, the NHS, the National Institute for Health Research (NIHR), PHE, UK Medical Research 307 308 Council (MRC), UK Research and Innovation, or the EU.

309

310 Funding

- This work was supported jointly by the Wellcome Trust and the Department for International Development (DFID; 311
- 312 221350)]. We acknowledge joint Centre funding from the UK MRC and DFID (MR/R015600/1). This work was also
- supported by the NIHR Health Protection Research Unit in Modelling Methodology, a partnership between PHE, 313
- Imperial College London, and London School of Hygiene & Tropical Medicine (NIHR200908), the Abdul Latif 314
- Jameel Foundation, and the EDCTP2 programme supported by the EU. LKW is funded by the Wellcome Trust 315
- (grant number 218669/Z/19/Z). 316
- 317

318 References

- Office for National Statistics. International comparisons of possible factors affecting excess mortality. 319 1.
- https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandwellbeing/articles/internat 320
- 321 ionalcomparisonsofpossiblefactorsaffectingexcessmortality/2022-12-20 (2022).
- Sachs, J. D. et al. The Lancet Commission on lessons for the future from the COVID-19 pandemic. The Lancet 322 2
- S0140673622015859 (2022) doi:10.1016/S0140-6736(22)01585-9. 323
- Office for National Statistics. Early insights into the impacts of the coronavirus (COVID-19) pandemic and EU 324 3. 325 exit on business supply chains in the UK.
- https://www.ons.gov.uk/businessindustryandtrade/internationaltrade/articles/earlyinsightsintotheimpactsofthecoro 326 naviruspandemicandeuexitonbusinesssupplychainsintheuk/february2021tofebruary2022 (2022). 327
- Fan, Y. et al. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Sig Transduct Target Ther 328 4
- 329 7, 141 (2022).
- 330 Tan, S. T. et al. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron 5. wave. Nat Med (2023) doi:10.1038/s41591-022-02138-x. 331
- Leung, K., Leung, G. M. & Wu, J. T. Modelling the adjustment of COVID-19 response and exit from dynamic 332 6.
- zero-COVID in China. http://medrxiv.org/lookup/doi/10.1101/2022.12.14.22283460 (2022) 333
- doi:10.1101/2022.12.14.22283460. 334
- 335 7. UK Government. COVID-19 Response - Living with COVID-19.
- https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1056229/COVI 336
- 337 D-19 Response - Living with COVID-19.pdf (2022).
- Knock, E. S. et al. Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in 338 8.
- England. Sci. Transl. Med. eabg4262 (2021) doi:10.1126/scitranslmed.abg4262. 339
- Sonabend, R. et al. Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in 340 9.
- England: a mathematical modelling study. The Lancet S0140673621022765 (2021) doi:10.1016/S0140-341
- 342 6736(21)02276-5.
- 10. Imai, N. et al. Ouantifying the impact of delaying the second COVID-19 vaccine dose in England: a mathematical 343
- modelling study. http://medrxiv.org/lookup/doi/10.1101/2022.08.08.22278528 (2022) 344
- 345 doi:10.1101/2022.08.08.22278528.

- 11. Docherty, A. B. *et al.* Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective
- 347 observational cohort study using the WHO Clinical Characterisation Protocol UK. *The Lancet Respiratory*
- 348 *Medicine* **9**, 773–785 (2021).
- 12. Nyberg, T. et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2
- omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. *The Lancet* **399**, 1303–1312
- 351 (2022).
- 13. The COVID-19 Genomics UK (COG-UK) consortium *et al.* Assessing transmissibility of SARS-CoV-2 lineage
- B.1.1.7 in England. *Nature* **593**, 266–269 (2021).
- 14. Cori, A., Ferguson, N. M., Fraser, C. & Cauchemez, S. A New Framework and Software to Estimate Time-
- Varying Reproduction Numbers During Epidemics. *American Journal of Epidemiology* **178**, 1505–1512 (2013).
- 15. Moya, A., Holmes, E. C. & González-Candelas, F. The population genetics and evolutionary epidemiology of
- 357 RNA viruses. *Nat Rev Microbiol* **2**, 279–288 (2004).
- 16. Mittal, A., Khattri, A. & Verma, V. Structural and antigenic variations in the spike protein of emerging SARS-
- 359 CoV-2 variants. *PLoS Pathog* **18**, e1010260 (2022).
- 17. UK Department of Health & Social Care. Chapter 8: non-pharmaceutical interventions.
- 361 https://www.gov.uk/government/publications/technical-report-on-the-covid-19-pandemic-in-the-uk/chapter-8-
- 362 non-pharmaceutical-interventions (2023).
- 18. UK Government. Prime Minister confirms move to Plan B in England.
- https://www.gov.uk/government/news/prime-minister-confirms-move-to-plan-b-in-england (2021).
- Bhattacharyya, R. P. & Hanage, W. P. Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron
 Variant. *N Engl J Med* 386, e14 (2022).
- 367 20. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med*368 384, 693–704 (2021).
- 369 21. Beigel, J. H. *et al.* Remdesivir for the Treatment of Covid-19 Final Report. *N Engl J Med* 383, 1813–1826
 370 (2020).
- 22. The Hospital Doctor's Union. COVID-19: Learning from the First Wave. Lessons for the NHS in the next phase
- and beyond. https://www.hcsa.com/media/154216/HCSA-Report-Covid19-Learning-from-the-First-Wave.pdf
- 373 (2020).

- 23. Perez-Guzman, P. N. et al. Clinical characteristics and predictors of outcomes of hospitalized patients with
- 375 COVID-19 in a multi-ethnic London NHS Trust: a retrospective cohort study. *Clinical Infectious Diseases*
- 376 ciaa1091 (2020) doi:10.1093/cid/ciaa1091.
- 24. Joint Committee on Vaccination and Immunisation. Joint Committee on Vaccination and Immunisation: advice
- 378 *on priority groups for COVID-19 vaccination.* 16
- 379 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/950113/jcvi-
- advice-on-priority-groups-for-covid-19-vaccination-30-dec-2020-revised.pdf (2020).
- World Health Organization. Tracking SARS-CoV-2 variants. https://www.who.int/activities/tracking-SARS CoV-2-variants (2023).
- 26. Imperial College COVID-19 Response Team *et al.* Estimating the effects of non-pharmaceutical interventions on
- 384 COVID-19 in Europe. *Nature* (2020) doi:10.1038/s41586-020-2405-7.
- 27. Dean, N. Tracking COVID-19 infections: time for change. *Nature* (2022).
- 28. Lin, L., Liu, Y., Tang, X. & He, D. The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of
 Concern. *Front. Public Health* 9, 775224 (2021).
- 29. Twohig, K. A. et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2)
- compared with alpha (B.1.1.7) variants of concern: a cohort study. *The Lancet Infectious Diseases* 22, 35–42
- 390 (2022).
- 30. Nyberg, T. et al. Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-
- 21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages. *The Journal of Infectious Diseases* 226, 808–
 811 (2022).
- 394 31. Kirwan, P. D. et al. Trends in risks of severe events and lengths of stay for COVID-19 hospitalisations in
- 395 England over the pre-vaccination era: results from the Public Health England SARI-Watch surveillance scheme.
- 396 45 https://arxiv.org/abs/2103.04867 (2021).
- 397 32. Brizzi, A. *et al.* Spatial and temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals. *Nat Med*398 (2022) doi:10.1038/s41591-022-01807-1.
- 399 33. Baguelin, M. *et al.* Vaccination against pandemic influenza A/H1N1v in England: A real-time economic
- 400 evaluation. *Vaccine* **28**, 2370–2384 (2010).

- 401 34. Baguelin, M., Jit, M., Miller, E. & Edmunds, W. J. Health and economic impact of the seasonal influenza
- 402 vaccination programme in England. *Vaccine* **30**, 3459–3462 (2012).
- 403 35. Baguelin, M., Camacho, A., Flasche, S. & Edmunds, W. J. Extending the elderly- and risk-group programme of
- 404 vaccination against seasonal influenza in England and Wales: a cost-effectiveness study. *BMC Med* 13, 236
- 405 (2015).
- 406 36. UK Government. *COVID-19 vaccine surveillance report: week 48.*
- 407 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1121345/vaccin
- 408 e-surveillance-report-week-48-2022.pdf (2022).
- 409 37. Bobrovitz, N. et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the
- 410 omicron variant and severe disease: a systematic review and meta-regression. *The Lancet Infectious Diseases*
- 411 S1473309922008015 (2023) doi:10.1016/S1473-3099(22)00801-5.
- 412 38. Murray, C. J. L. COVID-19 will continue but the end of the pandemic is near. *The Lancet* **399**, 417–419 (2022).
- 413 39. Endo, A. Introduction to particle Markov-chain Monte Carlo for disease dynamics modellers. 13 (2019).
- 414 40. UK Government. Coronavirus (COVID-19) in the UK. https://coronavirus.data.gov.uk (2022).
- 415 41. Imperial College COVID-19 Response Team. The REACT-1 programme.
- 416 https://www.imperial.ac.uk/medicine/research-and-impact/groups/react-study/.
- 417 42. Office for National Statistics. Coronavirus (COVID-19) Infection Survey, UK Statistical bulletins.
- 418 https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cor
- 419 onaviruscovid19infectionsurveypilot/previousReleases (2023).
- 420 43. Mossong, J. et al. Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases. PLoS Med
- 421 **5**, e74 (2008).
- 422 44. UK Government. Variants: distribution of case data, 6 May 2022.
- 423 https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-
- distribution-of-case-data-6-may-2022 (2022).
- 425
- 426

427 **Methods**

We expanded a previously described⁸⁻¹⁰ stochastic compartmental SARS-CoV-2 mathematical model and Bayesian 428 evidence synthesis framework, fitting to a range of epidemiological surveillance data streams using particle Markov 429 Chain Monte Carlo,³⁹ Data range between March 16, 2020 and February 24, 2022 and are aggregated by England 430 431 NHS (health administration) region. For a full description of the model structure, equations, parameters and fitted 432 data, see online Supplement. Briefly, our model has an SEIR structure, stratified in 17 age classes (5-year bands from 0 to 79 and 80+). We fitted to age-specific data on PCR case positivity from the community (national Pillar 2 433 programme),⁴⁰ infection PCR-positive prevalence survey from the REal-time Assessment of Community Transmission 434 (REACT) Study,⁴¹ hospital admissions, and community and hospital deaths, and daily number of first, second, and 435 booster vaccine doses,⁴⁰ and to regionally aggregated data on daily general and ICU bed occupancy,⁴⁰ and infection-436 PCR-positive prevalence from the Office for National Statistics.⁴² 437 438 To model heterogenous contact rates among age groups, we use the POLYMOD contact matrix for England.⁴³ We 439 then fit a piecewise linear, time-varying multiplier, β to account for changes in transmission given NPIs or other 440 official events, such as school holidays (Supplement Table S10). We use age-splines for the probabilities of severe 441 442 disease (requiring hospitalisation) conditional on infection, need for ICU care given hospitalisation and death in 443 hospital compartments (general bed, ICU, step-down care after ICU), as previously described.⁸ To account for 444 changes in healthcare characteristics, we further fit piecewise linear, time-varying modifiers of the probabilities of 445 hospitalisation given severe disease, ICU admission given hospitalisation, death in hospital and death in the 446 community, with dates defined either by official approval for key pharmacological treatments for COVID-19 in

447 England or changes in healthcare seeking behaviours (Supplement Tables S8 and S10).

448

Our model accommodates two circulating variants at a time over a sequence of three strain replacement phases; 449 450 namely, Wildtype and Alpha, Alpha and Delta, and Delta and Omicron. Within the two-variant model phases, infected compartments are further stratified into four classes, accounting for both primary infections and reinfections by each 451 of the circulating variants. Additionally, recovered compartments feature a fifth class, to account for those recovered 452 from an infection from a historic variant (e.g. during the Alpha and Delta phase, those recovered from a Wildtype 453 454 infection). A reinfection occurs when an individual in the recovered compartment is infected with a new variant. We

455 assume that an infection with a variant confers perfect immunity against that variant and variants that predate it (e.g. 456 prior infection with Omicron confers perfect immunity against Delta and Omicron). However, to model imperfect 457 protection from prior infection against emerging variants, we fix cross-immunity parameters as informed from the 458 literature (Supplement Table S9). To ensure the robustness of results, we varied fixed cross-immunity parameters 459 across a plausible range in sensitivity analyses (see Supplement section 5). We assume that individuals recovered from 460 an infection can lose all their infection-induced immunity and return to the susceptible compartment and their next 461 potential infection would be modelled as a new primary infection rather than a reinfection.

462

We model vaccination in seven classes (unvaccinated, dose one-no effect, dose one-full effect, dose two, waned from 463 dose two, booster dose, waned from booster) and we explicitly account for protection against infection, symptomatic 464 (mild) disease, severe disease requiring hospitalisation, death, and onward transmission (infectiousness). We assume 465 466 fixed degree-type protection from vaccine, informed by population-level English analyses by vaccine type and variant (Supplement Tables S3 and S4, and Figures S2-S5). To account for different vaccines used in England over the study 467 period, we used a multiplicative VE weighting for AstraZeneca and Pfizer/Moderna (assuming same efficacy between 468 the latter) uptake in the different age groups to daily data on first, second and booster doses administered by NHS 469 470 England region.

471

To robustly capture the variant-specific properties of transmissibility and severity, we fitted our model to regionally 472 aggregated data of variant frequency from Pillar 2 cases⁴⁴ for each variant transition. To infer variant transmissibility, 473 474 we fitted variant-specific parameters of their seeding date and transmission advantage relative to the variant being replaced. We assume a fixed seeding pattern for each variant and a gradual decrease in the serial interval over 475 476 successive variants as informed by the literature (Supplement Table S2). This latter assumption was also tested in 477 sensitivity analysis (Supplement section 5). For variant severity, we fitted variant-specific parameter multipliers of the 478 age-splines of the probabilities of hospitalisation conditional on infection, of ICU admission given hospitalisation, and 479 of death given infection. For each variant in succession, these multipliers were relative to the variant being replaced, independent of fitted time-varying healthcare severity parameters, and scaled (up or down) the age-specific severity 480 481 splines as a whole (assuming no age-specific changes in severity due to the variant).

483 We estimated the intrinsic R_0 and basic severity properties of the variants parametrically. For each NHS England region, the intrinsic R_0 was the product of the instantaneous reproduction number at the start of the model, $R_{t=0}$, and 484 485 the variant's transmission advantage relative to Wildtype. We fit the transmission advantage for each variant as a 486 parameter relative to the variant it replaces (e.g. Delta relative to Alpha). Lastly, we defined the basic severity of the 487 variants as what their infection hospitalisation (IHR), hospital fatality (HFR) and infection fatality ratios (IFR) would be in a population without any immunity (either from prior infections or vaccination) on the 16th of May 2020. Thus, 488 489 these basic severity measures allow us to compare variant severity in the absence of changes in severity over time or 490 in the age distribution of infections or hospitalisations, such as may be driven by vaccination or improvements in 491 healthcare. Given the stratification of our model compartments by age, vaccine and variant classes, coupled to our fitted splines of baseline severity pathways as described above, we were able to parametrically calculate the variant 492 specific IHR, HFR and IFR by age and vaccination class (see Supplement, section 4.3.4). We were then able to 493 remove the effect of vaccine-derived immunity by assessing these metrics in the unvaccinated classes only. To 494 495 account for the effect of the age distribution of infections or hospitalisation, we derived population-level basic IHR, 496 IFR or HFR by weighting age specific estimates across age groups using the eigenvector corresponding to the leading eigenvalue of the next-generation matrix used for ascertaining R_t . Since basic severity values are calculated with the 497 same scaling effects of the fitted time-varying severity modifiers for all variants, the effect of potential modifications 498 is standardised across variants. 499